Prescription injection Revonto recalled due to manufacturing temperature deviation
Revonto (dantrolene sodium) injection is being recalled due to manufacturing deviations involving temperature abuse. Approximately 49 cartons were distributed nationwide; healthcare providers should contact their supplier for guidance.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall of a precautionary nature due to manufacturing deviations (temperature abuse). No illnesses, injuries, or hospitalizations are reported. The hazard is potential drug stability or efficacy degradation from improper storage conditions.
Plain-English summary
Revonto (dantrolene sodium for injection), 20 mg/vial, is being recalled due to current good manufacturing practice (cGMP) deviations, specifically temperature abuse during the manufacturing process. The recall was initiated by McKesson Medical-Surgical Inc., the distributor, on behalf of the manufacturer US WorldMeds, Inc.
The recall involves approximately 49 cartons containing 6 vials each that were distributed to customers nationwide. The specific lot numbers affected vary by customer, and McKesson has communicated directly with affected consignees regarding the distribution dates and potential shipment dates relevant to each location.
Healthcare providers and pharmacies that received this product should consult the recall notification from McKesson for specific lot information and guidance. Patients currently using Revonto should speak with their healthcare provider before stopping or replacing their medication, as dantrolene sodium is a muscle relaxant with important medical uses.
The recalled product
- Product
- REVONTO (DANTROLENE SODIUM)
- Brand
- REVONTO
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Category
- Drug — Injectable
- Hazard
- temperature-abuse
- manufacturing-defect
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27